Preprint · 2021 · Open access

A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India

Prasad S. Kulkarni, Chandrasekaran Padmapriyadarshini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B S Garg, Nithya Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi and 20 more

SSRN Electronic Journal · Published 1 January 2021 · DOI 10.2139/ssrn.3901791

Open full textCite this paper

In brief

“A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India” is a 2021 preprint by Prasad S. Kulkarni and 31 co-authors, published in SSRN Electronic Journal. OpenAlex counts 1 citations as of 20 November 2026. It is open access: the full text is free to read at SSRN Electronic Journal.

Citations
1
Most cited in
2021 (1)
Authors
32

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kulkarni, P. S., Padmapriyadarshini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B. S., Gogtay, N., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S. R., Bhamare, C., Dharmadhikari, A., . . . COVISHIELD Study Group. (2021). A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3901791

MLA 9

Kulkarni, Prasad S., et al. “A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India.” SSRN Electronic Journal, 2021. https://doi.org/10.2139/ssrn.3901791.

Chicago

Kulkarni, Prasad S., Chandrasekaran Padmapriyadarshini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B S Garg, et al. 2021. “A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India.” SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3901791.

Harvard

Kulkarni, P. S. et al. (2021) ‘A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India’, SSRN Electronic Journal. doi:10.2139/ssrn.3901791.

IEEE

P. S. Kulkarni et al., “A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India,” SSRN Electronic Journal, 2021, doi: 10.2139/ssrn.3901791.

BibTeX

@misc{kulkarni2021phase,
  title     = {{A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India}},
  author    = {Kulkarni, Prasad S. and Padmapriyadarshini, Chandrasekaran and Vekemans, Johan and Bavdekar, Ashish and Gupta, Madhu and Kulkarni, Praveen and Garg, B S and Gogtay, Nithya and Tambe, Muralidhar and Lalwani, Sanjay and Singh, Kiranjit and Munshi, Renuka and Meshram, Sushant and Selvavinayagam, TS and Pandey, Krishna and Bhimarasetty, Devi Madhavi and Ramakrishnan, S. R. and Bhamare, Chetanraj and Dharmadhikari, Abhijeet and Vadakkedath, Rajeev and Bonhomme, Cyrille J. and Thakar, Madhuri Rajeev and Kurle, Swarali N. and Kelly, Elizabeth J. and Gautam, Manish and Gupta, Nivedita and Panda, Samiran and Bhargava, Balram and Shaligram, Umesh S. and Kapse, Dhananjay and others},
  howpublished = {SSRN Electronic Journal},
  year      = {2021},
  doi       = {10.2139/ssrn.3901791},
  url       = {https://doi.org/10.2139/ssrn.3901791}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • COVID-19 vaccines
  • ChAdOx1 nCoV-19 vaccine
  • AZD1222
  • immunogenicity
  • non-inferiority
  • anti-spike IgG
  • vaccine safety
  • serious adverse events

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Kulkarni, P. S., Padmapriyadarshini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B. S., Gogtay, N., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S. R., Bhamare, C., Dharmadhikari, A., . . . COVISHIELD Study Group. (2021). A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3901791

How many times has this paper been cited?

1 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at SSRN Electronic Journal: sign in and open the full text from this page.

Who wrote this paper?

Prasad S. Kulkarni, Chandrasekaran Padmapriyadarshini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B S Garg, Nithya Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi and 20 more.

What is the DOI of this paper?

10.2139/ssrn.3901791, permanently at https://doi.org/10.2139/ssrn.3901791. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.